Trial Profile
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms XanADu
- Sponsors Actinogen Medical
- 20 Jul 2023 Results assessing the effects of Xanamem on cognition from XanaHES (n= 42, 20 mg) and XanaMIA (n=105, 5 & 10 mg) and XanADu-X biomarker extension study (n=72, 10 mg), presented at the Alzheimer's Association International Conference 2023.
- 30 Mar 2023 Results published in the Actinogen Medical Media Release.
- 30 Mar 2023 According to Actinogen media release, CEO Dr. Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD 2023).